Cetera Advisor Networks LLC Xeris Biopharma Holdings, Inc. Transaction History

Cetera Advisor Networks LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$2.04 - $3.22 $1,213 - $1,915	595 Added 0.51%	117,585 $259,000
Q4 2023 Feb 13, 2024	BUY	$1.47 - $2.36 $6,914 - $11,101	4,704 Added 4.19%	116,990 $274,000
Q3 2023 Nov 14, 2023	BUY	$1.8 - $2.69 $2,608 - $3,897	1,449 Added 1.31%	112,286 $208,000
Q2 2023 Aug 09, 2023	BUY	$1.82 - $2.98 $11,951 - $19,569	6,567 Added 6.3%	110,837 $290,000
Q1 2023 May 15, 2023	BUY	$1.03 - $1.63 $20,490 - $32,427	19,894 Added 23.58%	104,270 $169,000
Q4 2022 Feb 14, 2023	SELL	$1.14 - $1.65 $76 - $110	-67 Reduced 0.08%	84,376 $112,000
Q3 2022 Nov 10, 2022	SELL	$1.37 - $1.93 $45,274 - $63,780	-33,047 Reduced 28.13%	84,443 $132,000
Q2 2022 Aug 11, 2022	BUY	$1.48 - $2.64 $38,234 - $68,201	25,834 Added 28.19%	117,490 $181,000
Q1 2022 May 12, 2022	BUY	$2.0 - $2.87 $12,562 - $18,026	6,281 Added 7.36%	91,656 $235,000
Q4 2021 Feb 14, 2022	BUY	$1.8 - $2.93 $153,675 - $250,148	85,375 New	85,375 $250,000

142

59.9M

148K

45.7K

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $458M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.